SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl is drawing attention after a strong Q3 earnings report, with traders highlighting better-than-expected results, growth in assets and fee-related earnings, and managements positive outlook on dividend coverage and future fees. Many expect sentiment to improve, while others remain cautious about private-credit redemptions and point to put-heavy options activity.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jasper Closes Kira Deal, Extends Cash Runway

Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2028. Shares surge 20%+.read more...

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million.
Kalaris Therapeutics (NASDAQ:KLRS) sharesread more...

Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate

Major M&A deals this week include: New Mountail Capital buys Asset Living, SalesForce acquires Contentful, Wellington nabs The Hartford Fundsread more...

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 88.6% in December

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totaling 3,455,246 shares, a...

Penny Stocks To Watch Now - December 2nd

Beyond Meat, Bitfarms, Fitell, Eventbrite, and Jasper Therapeutics are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small...

Jasper Stock Jumps After Promising New Asthma Study Results

Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.read more...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Jasper Therapeutics Inc

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

Equity

Bearish Sentiment

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Capricor Therapeutics Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.5202
Prev Close	$0.532
Open	$0.516
Dividend Yield	0.00%
50-Day Moving Average	$0.6018
Beta	1.46
Avg. Volume	384,643.48
PE Ratio	-0.33

52-Week High	$2.42
52-Week Low	$0.3151
Market Capitalization	$17.31M
EPS (Annual)	-$3.95
Price to Book	10.34
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

JSPR Fundamentals